CClinicalTrials.gg
WithdrawnNCT05229887Updated Sep 19, 2024

Confirmation of Tube Placement in Newborns

An interventional study of Nostril-Tragus-Length and Vocal cord marking in Respiratory Distress Syndrome and Apnea of Newborn, sponsored by University of Alberta. Withdrawn at 1 site in Canada. Open to participants aged Up to 3 Months. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

Why this study was withdrawn
need to be redesigned
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
Up to 3 Months
Sex
All
01

Study summary

Tracheal intubation remains a common procedure in the neonatal intensive care unit (NICU) and the delivery room (DR).

Current guidelines recommend Estimation of correct endotracheal tube (ETT) insertion Our hospital policy recommends to estimate the correct depth (cm) of tube placement by measuring the nasal-ear-tragus length using the "7-8-9 rule" when the endotracheal tube is placed orally. Using this formula an infant weighing 1kg would be intubated to a depth of 7cm, a 2kg infant to a depth of 8cm, and a 3kg infant to a depth of 9cm from the upper lip.

With the new 2015 guidelines, ETT depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm or by using the "initial endotracheal tube insertion depth" table. The NTL is described as the distance from the base of the nasal septum to the tragus of the ear.

However, studies using NTL reported that using this technique only resulted in correct ETT placement in 56% of cases.

Every ETT has markings on the tube, which are called vocal cord markings, which are to be used to provide a guidance to how deep to place the ETT into the trachea. There has been npc study to compare the vocal cord markings with the current approach of NTL.

The current study aims to determine if the use of vocal cord markings during intubation increases percentage of correct endotracheal tube placement compared to NTL in preterm and term infants.

02

Conditions studied

  • Respiratory Distress Syndrome
  • Apnea of Newborn
03

In context

Respiratory Distress Syndrome

1,597 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

University of Alberta is the lead sponsor of 800 studies on the registry; 168 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All infants (term and preterm) born at The Royal Alexandra Hospital who require endotracheal intubation in the delivery room or/and Neonatal Intensive Care Unit will be eligible.

Exclusion criteria

Exclusion Criteria:

  • Infants will be excluded if their parents refuse to give consent to this study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Nostril-Tragus-Length

    Procedure: Nostril-Tragus-Length

  • Experimental
    Vocal cord markings

    Procedure: Vocal cord marking

Interventions

  • ProcedureNostril-Tragus-Length

    Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm. The NTL is described as the distance from the base of the nasal septum to the tragus of the ear.

  • ProcedureVocal cord marking

    The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.

06

What researchers measure

Primary outcomes

  1. Number of endotracheal tubes correctly placed within the trachea

    Time frame: within 30 minutes after endotracheal intubation

Secondary outcomes

  1. Mortality in the Neonatal Intensive Care Unit

    We will record the number of infants who die during their admission

    Time frame: 0-200 days

  2. Necrotizing Enterocolitis

    We will record the number of infants who are diagnosed with Necrotizing Enterocolitis

    Time frame: 0-200 days

  3. Patent Ductus Arteriosus

    We will record the number of infants who are diagnosed with Patent Ductus Arteriosus

    Time frame: 0-200 days

  4. Intraventricular hemorrhage all grades

    We will record the number of infants who are diagnosed with intraventricular hemorrhage

    Time frame: 0-200 days

  5. Bronchopulmonary Dysplasia at

    We will record the number of infants who are diagnosed with Bronchopulmonary Dysplasia

    Time frame: 36 weeks corrected gestational age

  6. Changes in oxygen saturation during intubation procedure

    During intubation we will record the lowest oxygen saturation

    Time frame: 0 to 60 seconds

  7. Changes in Heart rate during intubation procedure

    During intubation we will record the lowest heart rate.

    Time frame: 0 to 60 seconds

  8. Duration of Intubation procedure

    During Intubation, we will measure time from end of mask ventilation to connection of the ventilation device to ETT

    Time frame: 0 to 60 seconds

  9. Airway injury observed during intubation (including blood, swollen cords, vocal cord redness)

    Observed by the person who performs the intubation by looking for blood, swollen cords, redness. There is no score or questionnaire. The operator will only assess these with yes or no

    Time frame: 0 to 60 seconds

07

Study locations

1 site
  • Royal Alexandra Hospital
    Edmonton, Alberta T5H 3V9, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Investigators can contact the PI to discuss to use the collected data

Supporting information: Study protocol, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05229887
Lead sponsor
University of Alberta
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
Jul 4, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Georg Schmolzer
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion